Light for Sight 21 was founded in 2011 during a candid discussion that Nikki Hafezi had with her husband, Farhad Hafezi, a keratoconus/cross-linking expert. She read in several scientific publications that the Down Syndrome population was more susceptible to have keratoconus than the general population. So, she asked her husband about why so few people with Down Syndrome are treated by corneal cross-linking (CXL), and how the Down Syndrome community is notified about this relatively new form of treatment of KC.
Only a few months later due to high demand, the “Light for Sight 21” project expanded to include all children and adolescents with keratoconus and given the general name of “Light for Sight.”
Her simple question is now uniting clinical institutions, research groups, patient organizations and the private sector in achieving the mission to eliminate severe visual impairment among all children and adolescents with keratoconus.
Introduction to Light for Sight – Nikki Hafezi
KMAP Study: Pilot study results, global infrastructure and next steps – Emilio Torres
Best Practice Model: How to build up patient referral networks – Nikki Hafezi
High Risk Patient Groups: Who are they (and why are they high-risk)? – Farhad Hafezi
Introduction to PINCO: first case study – Farhad Hafezi
Assessing clinical trial literature – Mark Hillen
Fluence and corneal thickness – Frederik Raiskup
Epi-off “Dresden” – Frederik Raiskup
CXL: Epi-off accelerated – Farhad Hafezi
State of the Art: PACK-CXL – Emilio Torres
Corneal biomechanics: modulating factors – Emilio Torres
Accelerated PACK-CXL as adjuvant treatment in infectious keratitis – Boris Knaizer